InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives - Seite 2

“Cheryl Tal joins us to lead our Quality Assurance and Regulatory Affairs function with tremendous expertise in building businesses’ scale and capacity on a global level.

“Finally, after six months as our General Manager of North America & VP of Global Marketing, Shane Gleason has been promoted to Chief Commercial Officer, expanding his responsibilities to support our global commercial growth, including continuing to advance our plans for the launch of CGuard Prime following a potential U.S. approval in the first half of 2025.

“I am very excited to announce these additions to our leadership team and I look forward to each of their contributions,” Mr. Slosman concluded.

Dr. Patrick Verta joins InspireMD from Canary Medical, a developer of implantable remote patient monitoring sensor technology and complementary data and analytics, where he served as Chief Medical Officer. Prior to that, he was Founder and Chief Executive Officer of Axelmed LLC, a consultancy focused on strategy and clinical, scientific, medical, and regulatory affairs for medical device companies. Before Axelmed, he spent the prior five years in various roles at Edwards Lifesciences, most recently as VP of Global Medical Affairs, Clinical Science and Biometrics in the Transcatheter Mitral and Tricuspid Therapies (TMTT) division. Earlier in his career, he held senior leadership positions at Sunshine Heart, Neomend, Abbott Vascular (part of Abbott) and Guidant (acquired by Abbott), among others. Dr. Verta received his Doctor of Medicine (M.D.) from Faculté de Médecine in Paris.

Cheryl Tal joins InspireMD from New Phase Ltd., where she served as Director of Regulatory Affairs. Prior to that, she served as Regulatory Affairs and Quality Assurance (RAQA) Manager at Change Healthcare (previously McKesson). Before that, she served as VP of Regulatory Affairs at ITGI Medical. Earlier in her career, Cheryl served in RAQA roles at Orsan Medical Technologies Ltd., Redent Nova Ltd., Galil Medical, Impliant Ltd., and A. Lapidot Pharmaceuticals Ltd.

Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
In connection with the appointment of Dr. Patrick Verta as Executive Vice President of Clinical and Medical Affairs, InspireMD has granted Dr. Verta 139,740 shares of restricted stock and stock options to purchase 46,580 shares of InspireMD’s common stock. The grant of restricted stock and stock options was approved by the Compensation Committee of InspireMD’s Board of Directors and was granted outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date of October 2, 2023, as an inducement material to Dr. Verta entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).